Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 9/20 | 0.34 |
| ▸ | CA1 | P00915 | 9/20 | 0.34 |
| ▸ | CA2 | P00918 | 9/20 | 0.34 |
| ▸ | CA9 | Q16790 | 9/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17635137 | 0.95 | CYP2D6 (0.37) | CYP2D6ALDH1A1MAPK1LMNAKMT2A | |
| SCHEMBL16656541 | 0.94 | CYP2D6 (0.36) | CYP2D6ALDH1A1MAPK1LMNAKMT2A | |
| SCHEMBL18346652 | 0.94 | CYP2D6 (0.36) | CYP2D6ALDH1A1MAPK1LMNAKMT2A | |
| SCHEMBL16656564 | 0.93 | CYP2D6 (0.35) | CYP2D6ALDH1A1MAPK1LMNAKMT2A | |
| SCHEMBL16656565 | 0.93 | CYP2D6 (0.35) | CYP2D6ALDH1A1MAPK1LMNAKMT2A | |
| SCHEMBL17549115 | 0.93 | CYP2D6 (0.32) | CYP2D6ALDH1A1MAPK1 | |
| SCHEMBL16418339 | 0.91 | LMNA (0.35) | CYP2D6ALDH1A1MAPK1LMNAKMT2A | |
| SCHEMBL16843439 | 0.89 | CYP2D6 (0.36) | CYP2D6ALDH1A1MAPK1LMNAKMT2A | |
| SCHEMBL18346604 | 0.89 | CYP2D6 (0.35) | CYP2D6ALDH1A1MAPK1LMNAKMT2A | |
| SCHEMBL14877068 | 0.88 | LMNA (0.45) | CYP2D6ALDH1A1MAPK1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9295730-B2 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS | INSTITUT PASTEUR (FR) | 2016-03-29 | — | — | US | disclosed |
| US-20110105412-A1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | UNIVERSITE PARIS-SUD (FR) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105412-A1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | CD4, CD40LG, CD40 | CYP2D6 3956/4885ALDH1A1 3919/4885MAPK1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.